U.S. Markets closed

Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ)

Shenzhen - Shenzhen Delayed Price. Currency in CNY
24.74+0.57 (+2.36%)
At close: 03:04PM CST

Nanjing Hicin Pharmaceutical Co., Ltd.

No.1 Hengfa Road
Eco & Tech Dev Zn
Nanjing 210046
86 25 8322 2911

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees563

Key Executives

NameTitlePayExercisedYear Born
Mr. Yuping CaoGM & ChairmanN/AN/A1964
Ms. Qinghua LiuCFO & Financial DirectorN/AN/A1970
Ms. Xiaomin YaoDeputy GM & DirectorN/AN/A1973
Mr. Yongjun WangDeputy GM & DirectorN/AN/A1965
Mr. Weicheng LiuDeputy Gen. Mang.N/AN/A1981
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.


Nanjing Hicin Pharmaceutical Co., Ltd. engages in the research, development, manufacture, marketing, and sale of pharmaceutical preparations and synthetic chemicals in China. The company offers antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for cardio-cerebral system, and immuno-modulate agents. It also provides technical transferring services. The company also exports APIs; omeprazole sodium and cefepime hydrochloride for injections; and lansoprazole tablets to South-Asian countries, South-American countries, and European countries. Nanjing Hicin Pharmaceutical Co., Ltd. was founded in 2003 and is based in Nanjing, China.

Corporate Governance

Nanjing Hicin Pharmaceutical Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.